My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

85.64 -2.94 (-3.32%)
Streaming Delayed Price Updated: 2:03 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today
Via Stocktwits
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High
The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months. 
Via Investor's Business Daily
Topics Intellectual Property
Cidara (CDTX) Q2 Cash Surges 163%
Via The Motley Fool
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories? 
Via MarketBeat
FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering
The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. 
Via Stocktwits
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Falls 1%; US Services PMI Declines In June
 
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality
The midstage study hit all its goals, representing a "best case" scenario, according to one analyst. 
Via Investor's Business Daily
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3. 
Via Benzinga
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results
 
Via Benzinga
Topics Stocks
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
These stocks are moving in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
Via Talk Markets
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Misses Revenue for Q2 2024
CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara... 
Via TheNewswire.com
Topics Regulatory Compliance
CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024
CDTX stock results show that Cidara Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.